Literature DB >> 18309957

Second-line therapy in gemcitabine-pretreated patients with advanced pancreatic cancer.

Stefan Boeck, Volker Heinemann.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18309957     DOI： 10.1200/JCO.2007.15.3304

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  9 in total

1.  Second-line therapy for gemcitabine-pretreated advanced or metastatic pancreatic cancer.

Authors:  Romain Altwegg; Marc Ychou; Vanessa Guillaumon; Simon Thezenas; Pierre Senesse; Nicolas Flori; Thibault Mazard; Ludovic Caillo; Stéphanie Faure; Emmanuelle Samalin; Eric Assenat
Journal:  World J Gastroenterol       Date:  2012-03-28       Impact factor: 5.742

2.  Use of gemcitabine as a second-line treatment following chemotherapy with folfirinox for metastatic pancreatic adenocarcinoma.

Authors:  Matthieu Sarabi; Laetitia Mais; Nadia Oussaid; Françoise Desseigne; Pierre Guibert; Christelle De La Fouchardiere
Journal:  Oncol Lett       Date:  2017-04-20       Impact factor: 2.967

3.  Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer.

Authors:  Brian M Wolpin; Aram F Hezel; Thomas Abrams; Lawrence S Blaszkowsky; Jeffrey A Meyerhardt; Jennifer A Chan; Peter C Enzinger; Brittany Allen; Jeffrey W Clark; David P Ryan; Charles S Fuchs
Journal:  J Clin Oncol       Date:  2008-12-01       Impact factor: 44.544

Review 4.  [Medical-oncological aspects in the treatment of pancreatic cancer].

Authors:  V Heinemann
Journal:  Radiologe       Date:  2009-02       Impact factor: 0.635

5.  A phase II study of flavopiridol (Alvocidib) in combination with docetaxel in refractory, metastatic pancreatic cancer.

Authors:  Richard D Carvajal; Archie Tse; Manish A Shah; Robert A Lefkowitz; Mithat Gonen; Lisa Gilman-Rosen; Jeremy Kortmansky; David P Kelsen; Gary K Schwartz; Eileen M O'Reilly
Journal:  Pancreatology       Date:  2009-05-19       Impact factor: 3.996

Review 6.  TTD consensus document on the diagnosis and management of exocrine pancreatic cancer.

Authors:  M Benavides; A Abad; I Ales; A Carrato; E Díaz Rubio; J Gallego; J García-Foncillas; C Grávalos; B Laquente; C Pericay; F Rivera; J Tabernero; E Aranda
Journal:  Clin Transl Oncol       Date:  2014-04-12       Impact factor: 3.405

7.  Significance of RRM1 and ERCC1 expression in resectable pancreatic adenocarcinoma.

Authors:  H Akita; Z Zheng; Y Takeda; C Kim; N Kittaka; S Kobayashi; S Marubashi; I Takemasa; H Nagano; K Dono; S Nakamori; M Monden; M Mori; Y Doki; G Bepler
Journal:  Oncogene       Date:  2009-06-22       Impact factor: 9.867

Review 8.  Advanced pancreatic carcinoma: current treatment and future challenges.

Authors:  Anastasios Stathis; Malcolm J Moore
Journal:  Nat Rev Clin Oncol       Date:  2010-01-26       Impact factor: 66.675

9.  A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer.

Authors:  C Yoo; J Y Hwang; J-E Kim; T W Kim; J S Lee; D H Park; S S Lee; D W Seo; S K Lee; M-H Kim; D J Han; S C Kim; J-L Lee
Journal:  Br J Cancer       Date:  2009-10-13       Impact factor: 7.640
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.